Lixte Biotechnology Files S-1 Registration

Ticker: LIXT · Form: S-1 · Filed: Apr 4, 2025 · CIK: 1335105

Lixte Biotechnology Holdings, INC. S-1 Filing Summary
FieldDetail
CompanyLixte Biotechnology Holdings, INC. (LIXT)
Form TypeS-1
Filed DateApr 4, 2025
Risk Levelmedium
Sentimentneutral

Sentiment: neutral

Topics: sec-filing, s-1, registration

TL;DR

Lixte Biotech just filed an S-1, get ready for a new offering.

AI Summary

Lixte Biotechnology Holdings, Inc. filed an S-1 registration statement on April 4, 2025, to register an unspecified number of securities. The company, incorporated in Delaware, is based in East Setauket, NY, with principal executive offices at 680 East Colorado Boulevard, Suite 180, Pasadena, CA 91101. Bastiaan van der Baan serves as the Chief Executive Officer.

Why It Matters

This S-1 filing indicates Lixte Biotechnology is preparing to offer new securities to the public, which could impact its capital structure and future operations.

Risk Assessment

Risk Level: medium — S-1 filings often precede significant corporate actions like stock offerings, which carry inherent market and execution risks.

Key Numbers

Key Players & Entities

FAQ

What is the purpose of this S-1 filing?

The S-1 filing is a registration statement required by the SEC for companies planning to offer securities to the public.

When was this S-1 filing submitted?

The S-1 filing was submitted on April 4, 2025.

Who is the Chief Executive Officer of Lixte Biotechnology Holdings, Inc.?

Bastiaan van der Baan is the Chief Executive Officer.

What is the principal executive office address?

The principal executive offices are located at 680 East Colorado Boulevard, Suite 180, Pasadena, CA 91101.

What is the SEC file number for this registration?

The SEC file number is 333-286385.

Filing Details

This Form S-1 (Form S-1) was filed with the SEC on April 4, 2025 by Bastiaan van der Baan regarding LIXTE BIOTECHNOLOGY HOLDINGS, INC. (LIXT).

View full filing on EDGAR

View Full Filing

View this S-1 filing on SEC EDGAR

View on Read The Filing